In the phase 3 OlympiAD trial, treatment with olaparib significantly improved progression-free survival and reduced the risk for disease progression or death compared with standard chemotherapy in women with HER2-negative, BRCA-mutated metastatic breast cancer.
After accounting for the benefit of pertuzumab, investigators found that >6 cycles of docetaxel did not significantly improve progression-free or overall survival in patients with HER2-positive, metastatic breast cancer.
Five-year analysis of the phase 3 ALTTO trial showed no decided benefit to dual HER2 blockade over single-agent HER2-targeted therapy for the treatment of HER2-positive early-stage breast cancer. However, an indication for dual HER2 blockade use in HER2-positive, estrogen receptor–negative tumors is a possibility.
A modest reduction in the risk for invasive breast cancer was achieved by adding a second HER2-targeted agent to the treatment regimen for women with early-stage HER2+ breast cancer. The results suggest that the strategy may be appropriate in women at highest risk for recurrence.